In a recent network meta-analysis, Freemantle et al. found that, compared with NPH insulin, Gla-300 provided a comparable change in HbA1c and body weight, with a significantly lower nocturnal hypoglycaemia rate (risk ratio: 0.18; 95% confidence interval: 0.05 to 0.55) [15]. The gene discussed is INS; the disease is Hypoglycemia.